Dr. Angelos M. Stergiou, MD,Sc D Hc
About Dr. Angelos M. Stergiou, MD,Sc D Hc
Angelos M. Stergiou, M.D., Sc.D. h.c., is a distinguished medical professional and executive with extensive experience in the pharmaceutical and biotechnology sectors, known for co-founding Genesis Life Sciences and leading the development of the cancer vaccine, BiovaxID.
Angelos M. Stergiou Company
Angelos M. Stergiou is the President and Chief Executive Officer, with a notable career path that spans various leadership roles within the pharmaceutical and biotechnology sectors. Notably, he co-founded Genesis Life Sciences, Ltd., where he served as President and Chief Operating Officer from 2009 to 2011. His leadership and entrepreneurial skills have significantly contributed to the health economics and pricing-reimbursement landscape.
Angelos M. Stergiou Education and Expertise
Angelos M. Stergiou earned a Doctor of Medicine from the U.S. American Institute of Medicine and was awarded a Doctor of Science (honoris causa) from Kentucky Wesleyan College. In addition, he completed his undergraduate studies at Kentucky Wesleyan College with a Bachelor of Sciences degree, majoring in Pre-Medicine, Biology, and Chemistry. He holds a patent on the technology used in the development of BiovaxID, underscoring his expertise in medical research and innovation.
Angelos M. Stergiou Background
From 2002 to 2009, Dr. Angelos M. Stergiou held global positions at various pharmaceutical and biotechnology companies, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International, and Anavex Life Sciences. His extensive background in these industries allowed him to lead the Phase 3 development of the therapeutic cancer vaccine BiovaxID, which was notably presented at the 2009 American Society of Clinical Oncology plenary session.
Angelos M. Stergiou Achievements
Among his numerous achievements, Dr. Angelos M. Stergiou's leadership in the development of BiovaxID stands out. He holds a patent for the technology used in this therapeutic cancer vaccine, which gained recognition at the American Society of Clinical Oncology plenary session in 2009. Additionally, as a Fellow of the Royal Society of Medicine, and as an active member of the World Medical Association, American Academy of Physicians in Clinical Research, and the Association of Clinical Research Professionals, he has established a strong presence in the medical research community.
Angelos M. Stergiou Board Memberships
Dr. Angelos M. Stergiou served on the Board of Trustees at Kentucky Wesleyan College from March 2017 to January 2021. He is currently on the Board of Directors at Cleara Biotech B.V., a biotech company located in the Netherlands, a position he has held since January 2022. These roles underscore his commitment to advancing education and biotechnology innovations.